BR112021014854A2 - Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis - Google Patents
Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisisInfo
- Publication number
- BR112021014854A2 BR112021014854A2 BR112021014854A BR112021014854A BR112021014854A2 BR 112021014854 A2 BR112021014854 A2 BR 112021014854A2 BR 112021014854 A BR112021014854 A BR 112021014854A BR 112021014854 A BR112021014854 A BR 112021014854A BR 112021014854 A2 BR112021014854 A2 BR 112021014854A2
- Authority
- BR
- Brazil
- Prior art keywords
- pruritus
- prurigo
- treatment
- nodularisis
- patients
- Prior art date
Links
- 208000003251 Pruritus Diseases 0.000 title abstract 5
- 206010037083 Prurigo Diseases 0.000 title abstract 3
- 206010040882 skin lesion Diseases 0.000 title abstract 2
- 231100000444 skin lesion Toxicity 0.000 title abstract 2
- 201000009053 Neurodermatitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229950010012 nemolizumab Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000017940 prurigo nodularis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis. são divulgados neste documento métodos para tratar seletivamente o prurido em um sujeito tendo prurigo crônico (cp), incluindo prurigo nodularis (pn), composições farmacêuticas para uso no tratamento de prurido em um sujeito com cp ou pn, usos de nemolizumabe ou um equivalente do mesmo na fabricação de um medicamento para o tratamento de prurido em um sujeito tendo cp ou pn.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797803P | 2019-01-28 | 2019-01-28 | |
| US201962809404P | 2019-02-22 | 2019-02-22 | |
| PCT/IB2020/050623 WO2020157636A1 (en) | 2019-01-28 | 2020-01-28 | Treatment of skin lesions and pruritus in prurigo nodularis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021014854A2 true BR112021014854A2 (pt) | 2021-12-21 |
Family
ID=69467604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021014854A BR112021014854A2 (pt) | 2019-01-28 | 2020-01-28 | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11236157B2 (pt) |
| EP (1) | EP3917617A1 (pt) |
| JP (4) | JP7410852B2 (pt) |
| KR (1) | KR20210122286A (pt) |
| CN (1) | CN113660981A (pt) |
| AU (1) | AU2020213978A1 (pt) |
| BR (1) | BR112021014854A2 (pt) |
| CA (1) | CA3127983A1 (pt) |
| CL (1) | CL2021001976A1 (pt) |
| IL (1) | IL285171A (pt) |
| MX (1) | MX2021009051A (pt) |
| SG (1) | SG11202108220YA (pt) |
| TW (1) | TW202043282A (pt) |
| WO (1) | WO2020157636A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023545182A (ja) * | 2020-10-15 | 2023-10-26 | インターベット インターナショナル ベー． フェー． | イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体 |
| US20220411518A1 (en) * | 2021-04-07 | 2022-12-29 | Galderma Holding S.A. | Treatments for prurigo nodularis |
| WO2023044313A1 (en) * | 2021-09-15 | 2023-03-23 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
| US20240141050A1 (en) * | 2022-09-02 | 2024-05-02 | Galderma Holding S.A. | Treatments for prurigo nodularis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| US20120220948A1 (en) | 2008-04-18 | 2012-08-30 | Ipsyrng Capital Development, Llc | Ergonomic syringe |
| DE102007056240A1 (de) | 2007-11-22 | 2009-05-28 | Henke-Sass, Wolf Gmbh | Spritze |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| NZ754639A (en) | 2015-08-24 | 2023-01-27 | Adamis Pharmaceuticals Corp | Syringe devices |
| KR101900427B1 (ko) | 2018-05-25 | 2018-09-20 | 송향숙 | 가압력 측정이 가능한 주사기용 보조그립 |
-
2020
- 2020-01-27 US US16/773,538 patent/US11236157B2/en active Active
- 2020-01-28 WO PCT/IB2020/050623 patent/WO2020157636A1/en active Application Filing
- 2020-01-28 EP EP20703537.9A patent/EP3917617A1/en active Pending
- 2020-01-28 SG SG11202108220YA patent/SG11202108220YA/en unknown
- 2020-01-28 CN CN202080011375.1A patent/CN113660981A/zh active Pending
- 2020-01-28 JP JP2020514620A patent/JP7410852B2/ja active Active
- 2020-01-28 AU AU2020213978A patent/AU2020213978A1/en active Pending
- 2020-01-28 KR KR1020217027603A patent/KR20210122286A/ko unknown
- 2020-01-28 BR BR112021014854A patent/BR112021014854A2/pt unknown
- 2020-01-28 MX MX2021009051A patent/MX2021009051A/es unknown
- 2020-01-28 CA CA3127983A patent/CA3127983A1/en active Pending
- 2020-01-30 TW TW109102901A patent/TW202043282A/zh unknown
-
2021
- 2021-07-27 IL IL285171A patent/IL285171A/en unknown
- 2021-07-27 CL CL2021001976A patent/CL2021001976A1/es unknown
- 2021-11-12 JP JP2021184447A patent/JP7309816B2/ja active Active
- 2021-12-20 US US17/555,997 patent/US20220177568A1/en active Pending
-
2023
- 2023-07-05 JP JP2023110385A patent/JP7375252B2/ja active Active
- 2023-10-25 JP JP2023183030A patent/JP2023182834A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023126909A (ja) | 2023-09-12 |
| TW202043282A (zh) | 2020-12-01 |
| IL285171A (en) | 2021-09-30 |
| EP3917617A1 (en) | 2021-12-08 |
| CL2021001976A1 (es) | 2022-02-11 |
| JP7375252B2 (ja) | 2023-11-07 |
| SG11202108220YA (en) | 2021-08-30 |
| JP2021509103A (ja) | 2021-03-18 |
| CN113660981A (zh) | 2021-11-16 |
| US20220177568A1 (en) | 2022-06-09 |
| KR20210122286A (ko) | 2021-10-08 |
| US11236157B2 (en) | 2022-02-01 |
| JP2023182834A (ja) | 2023-12-26 |
| MX2021009051A (es) | 2021-12-10 |
| WO2020157636A1 (en) | 2020-08-06 |
| AU2020213978A1 (en) | 2021-09-23 |
| CA3127983A1 (en) | 2020-08-06 |
| JP7309816B2 (ja) | 2023-07-18 |
| JP2022028788A (ja) | 2022-02-16 |
| US20200239563A1 (en) | 2020-07-30 |
| JP7410852B2 (ja) | 2024-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021014854A2 (pt) | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BR112023015045A2 (pt) | Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso | |
| BR112017019738A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| BR112022012637A2 (pt) | Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1 | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| BR112021016296A2 (pt) | Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| BR112017007545A2 (pt) | derivados de carbazol | |
| BR112022008558A2 (pt) | Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso | |
| BR112018074981A2 (pt) | tratamentos de câncer | |
| BR112016016880A2 (pt) | Combinação para tratar câncer e seu uso, kit, e composição farmacêutica | |
| BR112018074152A8 (pt) | Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico | |
| BR112016026545A8 (pt) | eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama | |
| BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
| BR112018002520A2 (pt) | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| CL2019000846A1 (es) | Proteína terapéutica. | |
| BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
| BR112018070847A2 (pt) | terapias combinadas para tratamento de câncer compreendendo um derivado de bacterioclorofila | |
| BR112021018858A2 (pt) | Chiauranibe para tratamento de câncer de pulmão de células pequenas | |
| BR112019001130A2 (pt) | uso de lactama e composição farmacêutica |